Optiscan Imaging’s endomicroscope being used in clinical gastroenterology study
Despite small numbers of patients, it highlights the need to discuss the risk versus benefits of live attenuated vaccines on a case-by-case basis. Another approach is to review the immunization status at diagnosis and give all recommended vaccines (e.g. varicella, hepatitis B) before commencing immunosuppressive therapy. This, however, is becoming a smaller window of opportunity with the earlier use of immunomodulatory therapy in IBD. A limitation of the study is the retrospective nature of the review in a state based IBD population. It was a representative sample of the database, but some IBD patients may have been excluded if seeing a private and/or adult gastroenterologist and not placed on the register. One major difficulty in conducting the study was uptake of ‘opt in’ consent, reflected by only 53% of adolescent and young adult patients being contactable. These are common issues in retrospective health related research and a number of surveys have explored the importance of exploring meaningful non-consent and considering ‘opt out’ consent [ 43 , 44 ]. The study was powered for 100 audit participants, but the results were affected by the low recruitment for the telephone immunization status review. The reported proportions of participants receiving the additional pneumococcal and influenza vaccines may not reflect the actual immunization status due to this incomplete record obtainment. The study was also underpowered to detect differences in the characteristics of those who received influenza vaccine. Another limitation is that the ACIR only routinely captures and maintains immunization records in children < 7 years of age, so added little information in this predominantly adolescent population. Whilst ACIR can include additional vaccines (e.g. influenza and pneumococcal), this information is not always captured. Suboptimal compliance with annual influenza vaccination and other additional vaccines recommended could be due to lack of awareness or acceptance of immunization guidelines for IBD patients.
source news http://www.biomedcentral.com/1471-230X/11/87
Optiscan Imaging (ASX: OIL) has noted commencement of a clinical study that is introducing Optiscan’s second generation endomicroscopy platform into the field of gastroenterology. The study is being undertaken by gastroenterologists and scientists from the Garvan Institute of Medical research and St Vincent’s Hospital in Sydney, in affiliation with the University of New South Wales. The gastroenterology market is now well established as a result of extensive use of Optiscan’s previous generation platform via a product marketed by Pentax Medical Corporation. The study has enabled the incorporation of the latest advances in Optiscan’s technology into a high definition Olympus endoscope. The resultant system combines advanced features of the Olympus endoscope with Optiscan’s latest developments in microscopic imaging during endoscopy. The result is an endoscope with a level of performance never before trialled in humans, incorporating desirable features discovered using the first generation product during thousands of endoscopy procedures, and other advances in endoscopic imaging. This study will apply these novel features in dynamic events relating to the permeability, or “leakiness” of the gut lining and how it is altered by inflammatory diseases. For Optiscan, the commencement of patient recruitment in this study is a key milestone in its strategy to advance the second generation platform into commercially viable markets. The same platform is currently the subject of product development for neurosurgery under a commercial partnership with Carl Zeiss of Germany, as well as a supply agreement recently secured with UK based MR Solutions for global supply into the pre-clinical imaging market. Optiscan is capitalised at around $10 million. Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX Small and Mid-cap stocks with distribution in Australia, UK, North America and Hong Kong / China.